GC Pharm cruising to commercialize flu vaccine for the elderly
GC Pharm has gotten a step closer to commercializing influenza vaccines that are more effective with the elderly.
GC Pharm(CEO Eun-Cheol Huh) announced on the 26th that they acquired approval of Phase II clinical trial for its high-volume quadrivalent influenza vaccine ‘GC3114’ from the Ministry...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.